TMP778 is a potent and selevtiveROR纬tinverse agonist, with an IC₅₀of 7 nM in FRET assay.

IC50: 7 nM (FRET assay), 63 nM (IL-17F promoter assay), 0.03 渭M (in Th17 cells), 0.005 渭M (in Tc17 cells)^[1].

It is found that TMP778 at >2.5 渭M starts to show toxic effects on cell growth, which however is not ROR纬t-dependent, since the proliferation of ROR纬t-deficient T cells cultured under Th17 cell-polarizing conditions is also decreased. Otherwise, these inhibitors do not show inhibitory effects on cell proliferation or ROR纬t expression or its nuclear translocation, but efficiently inhibited IL-17 production. TMP778 has a much broader dose range and efficiently decreased IL-17 production, consistent with its higher binding affinity for ROR纬t. These data indicate that TMP778 is the ROR纬t inhibitor that most potently reduced IL-17 production^[2].

All three compounds (e.g., TMP778) delay the onset of disease and substantially reduce the severity of disease progression compared to control-treated mice. Consistent with in vitro results, TMP778 treatment causes the most pronounced effect on the disease phenotype. This treatment not only decreases the number of mononuclear cells infiltrating the central nervous system (CNS), but also most strongly reduces the percentage of IL-17⁺T cells in the CNS (including IL-17⁺IFN纬⁺). There is no significant change in the percentage IFN纬⁺IL-17-T cells in the CNS among all groups, indicating that none of the inhibitors affects Th1 responses. TMP778 strongly inhibits Th17 cell generation, reduces IL-17 production from differentiated Th17 cells, and also dramatically ameliorates the progression of EAE^[2].

494.58

Solid

C₃₁H₃₀N₂O₄

1422053-04-0

Room temperature in continental US; may vary elsewhere.

DMSO : 240 mg/mL(485.26 mM;Need ultrasonic)